{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gan J"],"funding":["Shenkang 3-year project-Specialized clinical disease five new transformation project"],"pagination":["481"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6686499"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlling disease progression. Hence, identification of alternative treatments for patients is important. The Chinese herbal yinang formulation (YNF), which is derived from a Chinese patent medicine, appears to have a satisfactory effect in treating ADPKD. Because a considerable proportion of ADPKD patients presenting with chronic kidney disease (CKD) stages III-IV are diagnosed with the spleen, kidney deficiency, and blood stasis syndrome according to the diagnostic criteria of traditional Chinese medi"],"journal":["Trials"],"pubmed_title":["Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial."],"pmcid":["PMC6686499"],"funding_grant_id":["16CR3021A"],"pubmed_authors":["Yu S","Gan J","Ma Y","Gao J","Wu Y","Gong X"],"additional_accession":[]},"is_claimable":false,"name":"Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.","description":"<h4>Background</h4>Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlling disease progression. Hence, identification of alternative treatments for patients is important. The Chinese herbal yinang formulation (YNF), which is derived from a Chinese patent medicine, appears to have a satisfactory effect in treating ADPKD. Because a considerable proportion of ADPKD patients presenting with chronic kidney disease (CKD) stages III-IV are diagnosed with the spleen, kidney deficiency, and blood stasis syndrome according to the diagnostic criteria of traditional Chinese medi","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2025-04-22T20:27:14.588Z","creation":"2019-08-16T07:02:07Z"},"accession":"S-EPMC6686499","cross_references":{"pubmed":["31391092"],"doi":["10.1186/s13063-019-3563-5"]}}